Why Halozyme Therapeutics (HALO) is on investors’ radar today

Recent trading in Halozyme Therapeutics (HALO) has drawn attention, with the stock down around 4% over the past day and about 6% over the past week, prompting investors to reassess its current pricing.

At a share price of US$63.56, Halozyme’s recent 1 month share price decline of about 21% contrasts with a positive 3 month share price return of roughly 2% and a 1 year total shareholder return of around 4%. This suggests near term momentum has cooled while longer term holders have still seen gains.

If Halozyme’s recent swings have you thinking about where growth in healthcare could appear next, take a look at our screener of 34 healthcare AI stocks as potential ideas to research further.

With Halozyme trading at US$63.56 and sitting at a discount to some intrinsic estimates and analyst targets, the key question is whether the recent pullback has created an opening or if the market is already pricing in future growth.

Most Popular Narrative: 24.8% Undervalued

Halozyme Therapeutics’ most followed valuation narrative points to a fair value of about $84.50, compared with the recent share price of $63.56, putting that story in clear focus for investors trying to reconcile the recent pullback with longer term expectations.

The broadening market for biologic therapies, driven by an aging global population and increased incidence of chronic diseases, is materially expanding the addressable market for Halozyme's partners' therapies. With multiple new indication approvals (e.g., DARZALEX in smoldering multiple myeloma, VYVGART Hytrulo in CIDP) and expanding TAM, Halozyme is positioned for durable, high margin royalty revenue growth as partner drugs are increasingly prescribed to new patient populations.

Curious what sits behind that fair value gap? The narrative leans heavily on sustained royalty expansion, improving margins, and a future earnings base that assumes far more than today’s run rate. The exact growth and profitability path is spelled out in detail, along with the earnings multiple that would need to hold for that $84.50 figure to be supported.

Result: Fair Value of $84.50 (UNDERVALUED)

However, there are real pressure points here, including patent challenges around ENHANZE and heavy reliance on a few big partners that could unsettle that fair value story.

Another View: Earnings Multiple Sends a Different Signal

That $84.50 fair value story sits next to a very different message from the P/E ratio. At 23.7x earnings, Halozyme trades above the US Biotechs industry at 21.5x and above a fair ratio of 20.2x, which points to valuation risk rather than a clear margin of safety. So which signal do you trust more?

Next Steps

With mixed signals across fair value, earnings multiples and partner risks, it is worth checking the numbers yourself and deciding quickly where you stand, especially given there are 3 key rewards and 4 important warning signs.

Looking for more investment ideas?

If this Halozyme update has you rethinking your watchlist, do yourself a favor and scan a few broader ideas before the next move catches you off guard.

• Target value first and see which names our screener flags as 47 high quality undervalued stocks based on strong fundamentals and pricing that could be out of sync.
• Prioritise resilience and check out 68 resilient stocks with low risk scores if you want companies with steadier profiles that may help balance out more volatile positions.
• Hunt for future leaders early by reviewing our screener containing 25 high quality undiscovered gems that combine quality metrics with relatively low market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.